Live Breaking News & Updates on Prnewswire Inhibikase Therapeutics Inc

Stay updated with breaking news from Prnewswire inhibikase therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase. ....

United States , Milton Werner , Alex Lobo , Miltonh Werner , Inhibikase Therapeutics Inc , Prnewswire Inhibikase Therapeutics Inc , Company Contact , Sternir Inc , Exchange Commission , Inhibikase Or Company , Abelson Tyrosine Kinases , Chief Executive Officer , Abelson Tyrosine Kinase , Orphan Drug Designation , Chronic Myelogenous Leukemia , Ableson Tyrosine , Multiple System Atrophy , Private Securities Litigation Reform Act , Inhibikase Therapeutics ,

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

BOSTON and ATLANTA, Aug. 7, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of. ....

United States , Miltonh Werner , Alex Lobo , Inhibikase Therapeutics Inc , Company Contact , Inhibikase Or Company , Sternir Inc , Prnewswire Inhibikase Therapeutics Inc , Abelson Tyrosine Kinases , Abelson Tyrosine Kinase , Ableson Tyrosine , Multiple System Atrophy ,

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase. ....

United States , Alex Lobo , Miltonh Werner , Company Contact , Inhibikase Or Company , Exchange Commission , Prnewswire Inhibikase Therapeutics Inc , Sternir Inc , Nasdaq Stock Market , Inhibikase Therapeutics Inc , Abelson Tyrosine Kinases , Listing Qualifications Staff , Inhibikase Therapeutics , Nasdaq Listing Rule , Abelson Tyrosine Kinase , Ableson Tyrosine , Multiple System Atrophy , Private Securities Litigation Reform Act ,

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON and ATLANTA, July 17, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of. ....

United States , Miltonh Werner , Alex Lobo , Prnewswire Inhibikase Therapeutics Inc , Nasdaq Stock Market , Inhibikase Or Company , Company Contact , Sternir Inc , Inhibikase Therapeutics Inc , Exchange Commission , Abelson Tyrosine Kinases , Listing Qualifications Staff , Inhibikase Therapeutics , Nasdaq Listing Rule , Abelson Tyrosine Kinase , Ableson Tyrosine , Multiple System Atrophy , Private Securities Litigation Reform Act ,

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of ....

United States , Miltonh Werner , Alex Lobo , Inhibikase Or Company , American Stock Transfer Trust Company , Company Contact , Sternir Inc , Exchange Commission , Prnewswire Inhibikase Therapeutics Inc , Inhibikase Therapeutics Inc , Abelson Tyrosine Kinases , Nasdaq Capital Market , American Stock Transfer , Trust Company , Abelson Tyrosine Kinase , Ableson Tyrosine , Multiple System Atrophy , Private Securities Litigation Reform Act ,